Nasdaq moves to delist 60 Degrees Pharmaceuticals (SXTP) shares and warrants

Rhea-AI Filing Summary

60 Degrees Pharmaceuticals, Inc. (SXTP) reports that Nasdaq staff has determined to delist its common stock and warrants from The Nasdaq Capital Market. Nasdaq concluded the company failed to maintain the required minimum bid price of $1.00 per share for 30 consecutive business days under Listing Rule 5550(a)(2), and that it is not eligible for the usual 180‑day grace period because it completed a 1‑for‑5 reverse stock split on February 24, 2025 under Listing Rule 5810(c)(3)(A)(iv). The company’s warrants are also subject to delisting under Listing Rule 5560(a) because the underlying common stock is subject to delisting. The company has paid a $20,000 hearing fee and requested an appeal to a Nasdaq hearings panel, which temporarily stays any trading suspension and the filing of a Form 25‑NSE until the panel issues its decision.

Positive

• None.

Negative

• Nasdaq has moved to delist SXTP common stock and warrants after the shares failed to maintain a $1.00 minimum bid price for 30 consecutive business days and the company was denied a 180‑day cure period due to a recent reverse split.

Insights

Equity Markets & Listing Standards Analyst

Nasdaq has moved to delist SXTP shares and warrants, with only an appeal now standing between the company and loss of its Nasdaq listing.

The company states that Nasdaq staff determined its common stock failed to meet the $1.00 minimum bid price for 30 consecutive business days, triggering non‑compliance with Listing Rule 5550(a)(2). Because the company already executed a 1‑for‑5 reverse stock split on February 24, 2025, Nasdaq applied Listing Rule 5810(c)(3)(A)(iv) and did not grant the usual 180‑day cure period, moving directly toward delisting.

The warrants are also subject to delisting under Listing Rule 5560(a), since they rely on the common stock remaining listed. The company has paid a $20,000 hearing fee and requested an appeal, which it states stays the suspension of trading and the Form 25‑NSE filing until the panel issues its decision. The text notes there is no assurance the panel will allow continued listing, so the ultimate outcome depends on that future determination.

false 0001946563 DC 0001946563 2026-01-20 2026-01-20 0001946563 SXTP:CommonStockParValue0.0001PerShareMember 2026-01-20 2026-01-20 0001946563 SXTP:WarrantsEachWarrantToPurchaseOneShareOfCommonStockMember 2026-01-20 2026-01-20 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

PURSUANT TO SECTION 13 OR 15(d)

OF THE SECURITIES EXCHANGE ACT OF 1934

Date of Report (Date of earliest event reported): January 20, 2026

60 DEGREES PHARMACEUTICALS, INC.

(Exact name of registrant as specified in its charter)

Delaware		001-41719		45-2406880
(State or other jurisdiction of Incorporation)		(Commission File Number)		(IRS Employer Identification Number)

1025 Connecticut Avenue NW Suite 1000, Washington, D.C.		20036
(Address of registrant’s principal executive office)		(Zip code)

(202) 327-5422

(Registrant’s telephone number, including area code)

Not Applicable

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class		Trading symbol(s)		Name of each exchange on which registered
Common Stock, par value $0.0001 per share		SXTP		The Nasdaq Stock Market LLC
Warrants, each warrant to purchase one share of Common Stock		SXTPW		The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 3.01 Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing

On January 20, 2026, 60 Degrees Pharmaceuticals, Inc. (the “Company”) received a written notice (the “Notice”) from the Nasdaq Listing Qualifications Department of The Nasdaq Stock Market LLC (“Nasdaq”) indicating that Nasdaq staff has determined to delist the Company’s common stock and warrants from The Nasdaq Capital Market.

As disclosed in the Notice, Nasdaq staff determined that the Company’s common stock failed to maintain a minimum bid price of $1.00 per share for 30 consecutive business days, in violation of Nasdaq Listing Rule 5550(a)(2). While companies are typically afforded a 180-calendar-day compliance period to comply with the Nasdaq Listing Rule, Nasdaq staff concluded that the Company is not eligible for any compliance period pursuant to Nasdaq Listing Rule 5810(c)(3)(A)(iv) due to the fact that the Company effected a reverse stock split within the prior one-year period, specifically a 1-for-5 reverse stock split on February 24, 2025, and therefore is subject to immediate delisting.

Additionally, the Company’s warrants are subject to delisting pursuant to Nasdaq Listing Rule 5560(a), which requires the underlying security to be listed on Nasdaq.

As of the date of this current report, the Company has paid the $20,000 for the hearing fee and requested an appeal with Nasdaq, pursuant to the Notice, which shall stay the suspension of trading and the filing of the Form 25-NSE pending the Panel’s decision. There can be no assurance that the Panel will grant the Company’s request for continued listing.

Item 7.01. Regulation FD Disclosure

In accordance with Nasdaq Listing Rule 5810(b), the Company is issuing this Current Report on Form 8-K to publicly disclose receipt of the Nasdaq staff determination letter described above.

1

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

	60 DEGREES PHARMACEUTICALS, INC.
Date: January 23, 2026	By:	/s/ Geoffrey Dow
	Name:	Geoffrey Dow
	Title:	Chief Executive Officer and President

2

FAQ

Why is 60 Degrees Pharmaceuticals (SXTP) facing Nasdaq delisting?

Nasdaq staff determined that 60 Degrees Pharmaceuticals’ common stock did not maintain the required $1.00 minimum bid price for 30 consecutive business days, which violates Nasdaq Listing Rule 5550(a)(2). Because the company completed a 1‑for‑5 reverse stock split on February 24, 2025, Nasdaq applied Listing Rule 5810(c)(3)(A)(iv) and decided the company is not eligible for the usual 180‑day compliance period, leading to a determination to delist.

What happens to SXTP warrants under the Nasdaq determination?

The company states that its warrants are also subject to delisting pursuant to Nasdaq Listing Rule 5560(a), which requires that the underlying security be listed on Nasdaq. Because the common stock is subject to delisting, the warrants are as well.

Has 60 Degrees Pharmaceuticals (SXTP) appealed the Nasdaq delisting decision?

Yes. The company reports that it has requested an appeal of the Nasdaq staff determination and has paid a $20,000 hearing fee. According to the disclosure, this request for a hearing stays both the suspension of trading and the filing of the Form 25‑NSE until a Nasdaq panel issues its decision.

Did 60 Degrees Pharmaceuticals recently complete a reverse stock split?

Yes. The text notes that the company effected a 1‑for‑5 reverse stock split on February 24, 2025. Nasdaq cited this reverse split under Listing Rule 5810(c)(3)(A)(iv) as the reason SXTP is not eligible for any 180‑day compliance period for the minimum bid price rule and is instead subject to immediate delisting.

Is continued Nasdaq listing for SXTP guaranteed after the appeal?

No. The company explicitly states that there can be no assurance the Nasdaq hearings panel will grant its request for continued listing, indicating that the outcome of the appeal is uncertain based on the information provided.

What disclosure obligation did SXTP reference regarding this Nasdaq notice?

The company indicates that, in accordance with Nasdaq Listing Rule 5810(b), it is issuing this communication to publicly disclose receipt of the Nasdaq staff determination letter about the proposed delisting of its common stock and warrants.